The efficacy of a hemostatic agent in anticoagulant drug-induced rat bleeding model

Sönmez, Ertan; Çavuş, Umut Yücel; Civelek, Cemil; Dur, Ali; Karayel, Eda; Gülen, Bedia; Uysal, Ömer; İpek, Göktürk

doi:10.5505/tjtes.2014.54938

Cited by 4 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When new drugs are initially applied, researchers tend to pay more attention to their effects on the prevention of thrombus formation. However, an increasing number of studies have found that these drugs are associated with a higher incidence of bleeding [16, 17]. Therefore, we aimed to comprehensively analyse the thromboprophylactic drugs that are used to prevent thrombosis and reduce bleeding risk.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness and Tolerability of Anticoagulants for Thromboprophylaxis after Major Joint Surgery: a Network Meta-Analysis

Wang¹,

Zheng²,

Zhao³

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Venous thromboembolism (VTE) is the most common complication after major joint surgery. VTE can easily develop into pulmonary embolism (PE), leading to cardiopulmonary dysfunction or sudden death. We aimed to comprehensively analyse the thromboprophylactic drugs that are used to prevent thrombosis and reduce bleeding risk. Methods: We searched the PubMed, EMBASE, and Cochrane databases for randomized controlled trials that evaluated the use of thromboprophylaxis after major joint surgery. The major outcomes were the numbers of all-cause VTE and bleeding events, and the secondary outcomes were major VTE and major bleeding/clinically relevant non-major bleeding events. A random-effects network meta-analysis was used to assess the effectiveness and tolerability of each anticoagulant after major joint surgery. Results: We included 104 trials that assessed 110,643 patients in our meta-analysis. The cluster ranking of major outcomes indicated that FXI-ASO, ardeparin, aspirin, and apixaban were ideal for preventing all-cause VTE and avoiding all bleeding events. Nadroparin, recombinant hirudin, and rivaroxaban effectively inhibited VTE but were associated with a high risk of bleeding. For secondary outcomes, we found that betrixaban, dalteparin, warfarin, and eribaxaban were ideal for preventing major VTE and reducing major bleeding, while rivaroxaban effectively inhibited major VTE but was associated with a high risk of major/clinically relevant non-major bleeding. A sensitivity analysis showed that the effect of apixaban was more robust for major outcomes, while aspirin was more robust for preventing all-cause bleeding events. In secondary outcomes, the effect of warfarin was more robust, while apixaban was still considered an ideal treatment to inhibit major VTE and bleeding events. Conclusion: Our study indicates that FXI-ASO, ardeparin, aspirin, and apixaban are ideal for preventing all-cause VTE and reducing all bleeding events, among which apixaban is the most reliable. Betrixaban, dalteparin, warfarin, and eribaxaban are ideal for preventing major VTE and reducing major/clinically relevant non-major bleeding events, among which warfarin is the most reliable.

show abstract

Section: Introductionmentioning

confidence: 99%

Effectiveness and Tolerability of Anticoagulants for Thromboprophylaxis after Major Joint Surgery: a Network Meta-Analysis

Wang¹,

Zheng²,

Zhao³

et al. 2017

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…Sönmez et al . reported that APH which is a hemostatic agent with ultrahydrophilic and particulate properties has an effective hemostatic property in rats pretreated or nonpretreated with anticoagulants . It was found that the bleeding time in groups pretreated with warfarin and in the saline administered subgroup were 3.61 and 2.40 min, respectively.…”

Section: Resultsmentioning

confidence: 98%

Hemostatic activities of nano/microporous bilayer dressings in a femoral artery bleeding rat model

Karahaliloğlu

Demirbilek

Ulusoy

et al. 2016

J of Applied Polymer Sci

View full text Add to dashboard Cite

Recently, an effective hemostatic dressing requirement has become a major problem in both the military and civilian world. Available hemostatic agents are too expensive, ineffective, unsafe, or complicated to use. Here, we evaluated the hemostatic efficacy of a nano/micro bilayer hemostatic dressing including a porous sublayer from chitosan (CTS) and bacterial cellulose (BC) and a nanofibrillar upper layer from silk fibroin (SF). In addition, several active agents rolled in coagulation cascade [vitamin K (Vit K), protamine sulfate (PS), kaolin (Kao), etc.] were doped to the sublayer of bilayer hemostatic agent and their activities were compared via in vivo and in vitro tests. Lactate dehydrogenase (LDH) activity test results demonstrated that BC/CTS, SF-coated BC/CTS, and Vit K K/BC/CTS, SF/phosphatidylcholine (PC)-coated BC/CTS showed higher LDH activity compared to standard gauze (p < 0.005). In a femoral artery bleeding rat model, SF-coated PS/BC/CTS significantly reduced bleeding time (80 6 0.3 s) compared to standard gauze and kaolin-doped group (p < 0.005). Blood loss and mortality rate with 2.3 g and 37.5% SF-coated BC/CTS and SF-coated PS/BC/CTS showed increased efficacy in achieving hemostasis compared to standard gauze. All the prepared hemostatic dressings except for kaolin-doped BC/CTS and standard gauze induced no inflammatory reaction in the tissue. All these data suggest that active agent-doped BC/CTS/SF-based bilayer hemostatic dressings have a great influence on the resulting hemostatic action. V C 2016 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2016, 133, 43657.

show abstract

“…If location of the bleeding is unknown, those in the form of a leakage, pressure method or vasoconstrictor agents can be used. Nowadays, hemostatic agents are used in a wide-range of operation and have been reported by many researchers as effective in controlling bleeding 7 .…”

Section: Discussionmentioning

confidence: 99%

Hemostatic Effects of A-fact, which is a new hemostatic agent

Hepokur¹,

Mısır²,

Özbek³

2018

Cumhuriyet Medical Journal

View full text Add to dashboard Cite

A-Fact is a solution contains iron (II) sulfate and forms an iron-ion-protein complex. An ideal hemostatic agent should have been stopping venous bleeding after being applied to the lesion. Our aim in the present study is to investigate the in vitro effects of A-Fact on hemostatic parameters. Method: Plasma pooling was performed by centrifuging venous blood samples from volunteer people. Total protein, fibrinogen activity, albumin and globulin, coagulation factor (II, VII, IX) levels were analyzed with spectrophotometric method in auto analyzer by applying different concentrations of A-Fact. Microscopic images were obtained by applying 5%, 10%, 15% and 50% A-fact to blood samples for morphological evaluation. Results: A-Fact ensured the formation of the iron-ion-protein complex. Coagulation tests were performed by 2/20 dilution. A-Fact was not effect on coagulation factors. Plasma fibrinogen activity, total protein, albumin and globulin levels were decreased while prothrombin time was prolonged. Furthermore, it was observed that A-Fact caused an increase in INR values. Conclusions: In this study, it was showed that the bleeding-stopping effect of A-Fact may be caused by protein formation. It is clear that further studies are needed in this area.

show abstract

The efficacy of a hemostatic agent in anticoagulant drug-induced rat bleeding model

Abstract: BACKGROUND:Bleeding is a major problem in warfarin pretreated patients who need emergency surgical procedures. APH is a hemostatic agent with ultra-hydrophilic and particulate properties. This study aimed to evaluate the in vivo hemostatic effect of APH in rats pretreated with warfarin.

Cited by 4 publications

References 25 publications

Effectiveness and Tolerability of Anticoagulants for Thromboprophylaxis after Major Joint Surgery: a Network Meta-Analysis

Effectiveness and Tolerability of Anticoagulants for Thromboprophylaxis after Major Joint Surgery: a Network Meta-Analysis

Hemostatic activities of nano/microporous bilayer dressings in a femoral artery bleeding rat model

Hemostatic Effects of A-fact, which is a new hemostatic agent

Contact Info

Product

Resources

About